Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.56 USD | +0.08% | +0.20% | +58.46% |
Financials (USD)
Sales 2024 * | 204M | Sales 2025 * | 264M | Capitalization | 2.21B |
---|---|---|---|---|---|
Net income 2024 * | -185M | Net income 2025 * | -156M | EV / Sales 2024 * | 10.8 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8.37 x |
P/E ratio 2024 * |
-12.4
x | P/E ratio 2025 * |
-15.7
x | Employees | 355 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.52% |
Latest transcript on Deciphera Pharmaceuticals, Inc.
1 day | +0.08% | ||
1 week | +0.20% | ||
Current month | +0.08% | ||
1 month | +0.71% | ||
3 months | +47.24% | ||
6 months | +97.53% | ||
Current year | +58.46% |
Managers | Title | Age | Since |
---|---|---|---|
Steven Hoerter
CEO | Chief Executive Officer | 53 | 18-05-16 |
Tucker Kelly
DFI | Director of Finance/CFO | 53 | 15-01-31 |
Kevin Brodbeck
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patricia Allen
BRD | Director/Board Member | 62 | 16-08-31 |
Edward Benz
BRD | Director/Board Member | 78 | 19-06-30 |
Ron Squarer
CHM | Chairman | 57 | 19-12-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - | |
0.05% | 2 M€ | -.--% | ||
0.04% | 234 M€ | +8.93% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 25.56 | +0.08% | 1,415,926 |
24-05-31 | 25.54 | +0.04% | 1,854,493 |
24-05-30 | 25.53 | +0.08% | 701,005 |
24-05-29 | 25.51 | 0.00% | 1,062,075 |
Delayed Quote Nasdaq, June 03, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+58.46% | 2.21B | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- DCPH Stock